Acutus Builds On Arrhythmia Mapping Success With New Ablation Devices
Executive Summary
The company is supporting two US trials of the AcQBlate Force ablation catheter to support FDA approval of the system to treat atrial flutter and atrial fibrillation.
You may also be interested in...
Vince Burgess Steps Down After Nine Years As Acutus CEO
Analysts believe the company’s arrythmia mapping technology could potentially disrupt the electrophysiology mapping market, but are disappointed with Acutus’ growth so far.
Acutus Sells Left-Heart Access Business To Medtronic; Extends Its Cash Runway
The deal, potentially worth more than $85m, will allow Acutus to get more revenue from its core AcQMap electrophysiology mapping technology and invest in the development of its pulsed field ablation system.
Acutus Cuts Jobs To Reduce Cash Burn, Drive Adoption Of Cardiac Mapping System
The electrophysiology company announced it will reduce its workforce and take other cost-reduction measures to reduce its annual spending by $23m-$25m. Analysts suspect the company will need to raise more money from investors in 2022 or try to be acquired by a larger company.